Multidisciplinary Cutaneous Lymphoma Group

Closed Trials

A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients with Refractory Cutaneous T-Cell Lymphoma

This is a multi-center Phase I, open-label, trial testing the efficacy of oral Forodesine Hydrochloride in patients with previously treated, refractory CTCL Stage IB or greater. This trial is being sponsored by BioCryst Pharmaceuticals, Inc. Patients will receive continuous oral daily dosing with forodesine hydrochloride for a total of 4 weeks, or 28 days. There are at least 8 visits to Stanford that must be done.

Phase IIB Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma

This multicenter phase IIB trial investigating Suberoylanilide Hydroxamic Acid (SAHA), a potent inhibitor of the activity of histone deacetylase, is being sponsored by New York-based Aton Pharmaceutical. This study is for patients with advanced CTCL (Stage IB or higher) who have progressive, persistent, or recurrent disease on or following two systemic therapies one of which must contain Targretin (bexarotene) unless the patient is intolerant of or not a candidate for Targretin (bexarotene) therapy.

A Phase II Open-Label Study of Recombinant Human Interleukin-12 (NSC 672423) in Mycosis Fungoides (MF) Patients with Cross-over to Phase I Evaluation of Escalating Doses of Interleukin-2 (NSC 373364) Administered with Interleukin-12

This is a seven and a half month (7 ½) phase II multicenter trial investigating the experimental drug recombinant human interleukin-12 (rhIL-12), and another drug, recombinant interleukin-2 (IL-2), may be added unless the patient has disease progression. This study is for mycosis fungoides, stage IB or greater.

A Phase I/II Open label, Multi-Center Study for the Evaluation of CpG 7909 in Patients with Stage IB to IVA Cutaneous T-Cell Lymphoma

The Coley Pharmaceutical Group is sponsoring this multi-center phase I/II trial investigating the immunostimulatory oligodeoxynucleotide, CpG 7909, for the treatment of patients with stage IB to IVA mycosis fungoides who have received at least one and no more than three prior systemic regimens, including PUVA.

A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Primary Cutaneous Anaplastic Large Cell Lymphoma

Seattle Genetics is sponsoring a phase II trial of SGN-30 for patients with CD30+ malignancies. SGN-30 is the chimeric form of a novel murine monoclonal antibody (mAb), AC-10, that has specificity for CD30 that is unique from other anti-CD30 antibodies.

Footer Links: